Longevityresearch.ca publishes cross-disease causal analysis quantifying endpoint reduction across 27 diseases

By: PRLog

June 23, 2026 at 12:33 PM EDT

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

TORONTO - June 23, 2026 - PRLog -- An open Bayesian Causal Atlas now reports, for every disease it covers — including non-fatal conditions — the best-case modelled reduction achievable when all applicable beneficial interventions are combined under a Pearl structural-causal framework.

Longevity Research (longevityresearch.ca), an independent quantitative-research project, today released a cross-oracle analysis that computes, for each disease in its Bayesian Causal Atlas, the maximum modelled reduction in that disease's own endpoint when every applicable beneficial intervention is combined at full dose under the project's causal model.

The analysis covers 27 disease models in a single comparable table — spanning all-cause mortality, cardiovascular disease (18 phenotypes), cancer (18 sites), kidney disease, immunology (45 conditions), pulmonary disease, brain tumours, organ transplant, and more — and, unlike most mortality-focused work, it deliberately includes endpoints that are not death: allergy flares, kidney-function decline, disability progression, and other quality-of-life outcomes.

Longevity Research is an independent, non-commercial quantitative-research project that applies Bayesian causal inference to the leading causes of mortality and to chronic disease. Its Bayesian Causal Atlas is a free, open set of interactive analyses intended for people managing serious illness, their caregivers, and researchers. The site runs no advertising and collects no user data.

https://longevityresearch.ca/

Contact
Stuart Berkowitz
***@longevityresearch.ca

Source: ASCL

Read Full Story - Longevityresearch.ca publishes cross-disease causal analysis quantifying endpoint reduction across 27 diseases | More news from this source

Press release distribution by PRLog

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Symbol	Price	Change (%)
AMZN	227.01	-7.26 (-3.10%)
AAPL	275.15	-17.93 (-6.12%)
AMD	532.57	+12.83 (2.47%)
BAC	58.19	+0.46 (0.80%)
GOOG	342.19	-2.85 (-0.83%)
META	542.87	-14.80 (-2.65%)
MSFT	352.83	-12.63 (-3.46%)
NVDA	195.74	-3.26 (-1.64%)
ORCL	152.46	-5.07 (-3.22%)
TSLA	375.12	-0.41 (-0.11%)

Symbol

Price

Change (%)

AMZN

227.01

-7.26 (-3.10%)

AAPL

275.15

-17.93 (-6.12%)

AMD

532.57

+12.83 (2.47%)

BAC

58.19

+0.46 (0.80%)

GOOG

342.19

-2.85 (-0.83%)

Longevityresearch.ca publishes cross-disease causal analysis quantifying endpoint reduction across 27 diseases

More News

Recent Quotes